## Chelsea and Westminster Hospital NHS

intinteraction<			vin chinical trials gran	tea NHS Permis:	NHS Permission between 01 January 2014 - 31 December 2014						
Image: Note: Interpretation of the section of the	Reference	Committee	Name of Trial		Valid Research		Patient	between VRA and		Reason for Delay	
BandorsMarket in Proceedings of the interaction of the interacti	&W14/111	10/H1107/70	Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?	26/11/2014	20/11/2014	No	Pending	Not applicable	Pending	Deadline is 29 January 2015.	
AntendedLabel and antender in the intervence in the intervence in the intervence inte	&W12/074	12/NW/0214	Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Individuals on Combination	12/05/2014	12/05/2014	Yes	20/06/2014	39	Yes		
$\omega_{1}$ and $\omega_{2}$ Number heady is proved in the provide the	C&W14/069	12/SC/0014	Vascpressin vs Noradrenaline as Initial therapy in Septic Shock (VANISH)	15/07/2014	07/07/2014	No	Pending	Not applicable	No	Source of delays: Sponsor D - Delays caused by sponsor: spons reluxed to grant grane high for security following NHS Permission because of revised training requirements put in p by sponsor. Green light for recultiment received on 2020/20214, which was 5 days following VRA. F. No eligible patients soles are during the reporting period: patients sought but r eligible patients being screened.	
ART 12.0001Ander one inclusion control of original control original	&W13/085	13/EE/0270	A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain	04/07/2014	30/06/2014	Yes	15/07/2014	15	Yes		
Sector     Sector<	C&W13/094	13/EM0154	A multi-centre randomised controlled trial evaluating cast treatment versus surgical fixation on wrist function for fractures	13/01/2014	13/01/2014	No	Pending	Not applicable	No	D - Delays caused by sponsor: protoc amendments implemented by sponsor organisation meant that recuritment p were were not received by site within 70 day pariod. E - Staff analolity issues at site: Following 70 day priod; staff anarge study. Performantificients billing to am study. Performante management plan implemented between Trust and spon with a review date of 06/10/2014. Out of review has been withdrawal of NHS Permission following consultation with emission study.	
Market MARTINOSubscriptionIntermediate displaced data set on in menocolder displaced data set on poly-generation of a data too in menocolder displaced data set on poly-generation of a data too in menocolder data and poly-generation data data menocolder data data data data data data data dat	&W14/004	13/LO/0147	concentration of Maraviroc required for ex vivo protection from	10/03/2014	04/03/2014	Yes	10/06/2014	98	No	Source of delays: Sponsor D - Delays caused by sponsor: spons relused to grant gene hight for record for the sponsor of the second second criteria to hepitata A screening (best criteria to hepitata A screening (best criteria) (best a screening (best criteria) (best criteria) (best a screening (best criteria) (best a screening (best criteria) (best criteria) (best a screening (best criteria) (bes	
AWT 14022 13 SC 0.48 ASAP - Early for does straids for adults attimited to hospital abult or documented bial straids of trainability and the straids in a straids of the straids in abult of trainability and the straids in a straid of trainability and trainability and trainability and trainability and trainability and abult of trainability and trainability and abult of trainability and trainability and trainability and trainability and trainability and abult of trainability and trainability and trainability and trainability and abult of trainability and trainability and trainability and trainability and abult of trainability and trainability and trainability and trainability and trainability and abult of trainability and trainability and trainability and trainability and trainability and trainability and abult of trainability and trainability and trainability and trainability and trainability and abult of trainability and trainability an	C&W13/100	13/LO/1908	fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP's) in children with	17/02/2014	13/02/2014	Yes	28/04/2014	74	No	G - Eligible patients seen during the relevant period but did not consent to participate in the trial - 2 were given in prior to deadline but due to Easter we unable to be scheduled in in time. The fault therefore lies neither with the NH- Provider nor sponsor - patients would consented if the public holiday fell on	
Art No.02     Patients at Risk of Resurrence of Versus Transbounders     OF/10/201     OF/10/201     OF/10/201     OF/10/201     OF/10/201     Call	C&W14/022	13/SC/0436	with influenza-like illness during a pandemic: a randomised	18/06/2014	18/06/2014	No	Pending	Not applicable		Source of delays: Neither Sponsor NHS J - Other: study will sit in hibernation until C&W is activated as a research the event of a pandemic flu episode. I will only be activated by sponsor, and therefore become open to recruitmen when a pandemic flu event is declare	
ZAV113000     14/EE0048     Acceptation between thermal imaging phemography and phanes     Zav012014     1701/2014     Yes     05/03/2014     47     Yes       ZAV14022     14/EE0048     The effects of electronic cigaretes on the microcluster of an DAT     31/07/2014     31/07/2014     Yes     25/08/2014     25     Yes     2       ZAV14042     14/EE0198     The effects of electronic cigaretes on the microcluster of an DAT     31/07/2014     31/07/2014     Yes     25/08/2014     28     Yes     2       ZAV14042     14/EE/1083     Copan Label, Randomized Study of ZD2291 with Locally Animeted Vision Single Cell Long to the Loginary Animeted Vision Single Cell Long to the Long Vision Name Cell Long Long Long Long Long Long Long Long	C&W14/029	13/WM/0017	select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism	07/07/2014	07/07/2014	Yes	08/08/2014	32	Yes		
AMP14025     14EED188     The effector of electronic digreters on the microcirculation of the hund     3107/2014     Yes     2508/2014     25     Yes       XW14046     14EE/1027     Widding and Echalization accore to grade physical Assessment Too (CPA); weexers from official filmss.     6000/2014     21.08/2014     Yes     1809/2014     28     Yes     1809/2014     28     Yes     1809/2014     Yes     1809/2014     Yes     1809/2014     13     Yes     1809/2014     Yes     01/10/2014     13     Yes     1208/2014     Yes     01/10/2014     13     Yes     1208/2014     Yes     1208/2014     Yes     01/10/2014     14     Yes     1208/2014     Yes     1208/2014     Yes     1208/2014     Yes     1208/2014     Yes     1208/2014     14     Yes     1208/2014     1208/2014     1208/2014	&W13/090	14/EE/0048	A comparison between thermal imaging (thermography) and	23/01/2014	17/01/2014	Yes	05/03/2014	47	Yes		
AW14046   14/EE/1027   The Chelles Chical Care Physical Assessment Tod (CPA): recovery from chical lines:   08/08/2014   21/08/2014   Yes   18/08/2014   28   Yes     AW14046   14/EE/1027   A Phase III. Open Labol, Randon of Adduttory of AZ020201 with Lobel Assessment State (Net) To Parity Cancer whose Disease has Progressed with Previous Epidemic Twen Factor Receptor Yosine Rinks Inchibits and the Epidemic Town Factor Receptor Yosine Rinks Inchibits Therapy and whose Tumous hafters a T750M mutation with in the Epidemic Town Factor Receptor Yosine Rinks Inchibits and the Epidemic Town Factor Receptor Regime of MASTER/RECEPTOR and the Epidemic Rinks Inchibits and the Rinks Inchibits and the Rinks Inchibits Inchibits and the Rinks Inch	&W14/025	14/EE/0188	The effects of electronic cigarettes on the microcirculation of	31/07/2014	31/07/2014	Yes	25/08/2014	25	Yes		
APtase II, Open Label, Randomized Study of AZD9291 versus Platfurm-Based Double Chemotherapy for Platents in Coaly Advinced Matatatic Non-Small Cell Lung Cancer whole Disease has Progressed with Previous Theory and whole Turnois hatobia: TSP00 mutatato mething and whole Turnois hatobia: TSP00 mutatato muthin the Epidemal Growth Patter Receptor Gene 18/09/2014 18/09/2014 13 Yes   &W14002 144.L00033 Ar open label study scanning the efficacy and cardiovascular model of mutatic transmits and the study scanning the efficacy and set of mutatic transmits and the study scanning the efficacy and set of mutatic transmits and the study scanning the efficacy and set of the study scanning the study scanning the study study scanning the study scanning the study scanning the study study scanning the study scanning the study scanning the study study scanning scanning study scanning sc	&W14/046	14/EE/1027	The Chelsea Critical Care Physical Assessment Tool (CPAx): Validation and Evaluation of a score to grade physical	08/09/2014	21/08/2014	Yes	18/09/2014	28	Yes		
28W14002   14L.00083   risk of immediate virus deferred with from a boosted P1b of virus deferred with stable virus deferred with with virus deferred with stable virus deferred with with virus deferred with Wire deferred with def	C&W14/079	14/EE/1063	A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Smail Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumour sharbour a TP30M mutation	18/09/2014	18/09/2014	Yes	01/10/2014	13	Yes		
Sately of the Combination Regiment of MK-S172/MK-S742 in Transmen-Naive Subjects with Chronic Hyperbane (SMC S742).   1206/2014   Yes   1306/2014   4   Yes     24W14068   144_008677   Stately of the Combination Regiment of MK-S172/MK-S742 in and GT6 Intelector with HW   1206/2014   Yes   1306/2014   4   Yes     24W14066   144_008687   Financokneids (Jabeco Controlled, Multiple-Does Study to Evaluate the Pharmacokneids (Jabeco Controlled, Multiple- ter)   1400/2014   140/2014   Yes   2108/2014   2   Yes     28W14098   144_LO1430   A Phase IM Multicenter, Tandomised, dual-arm, placetor   130/2014   19/12/2014   Ves   25/11/2014   21   Yes   28/11/2014   Yes   25/11/2014   Yes   25/11/2014   2 <td>C&amp;W14/002</td> <td>14/LO/0083</td> <td>risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable</td> <td>08/04/2014</td> <td>08/04/2014</td> <td>Yes</td> <td>02/05/2014</td> <td>24</td> <td>Yes</td> <td></td>	C&W14/002	14/LO/0083	risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable	08/04/2014	08/04/2014	Yes	02/05/2014	24	Yes		
AW14066   144_00803   Pharmacohymanics, Safety and post-spectra with automative scale Billing and BMS- 955178 with Autamativ 4 Ritoria (Open-Labeled) in HIV-1 intractal Safets   1407/2014   1107/2014   Yes   2807/2014   18   Yes     XW14087   144_071227   Ploamacohinetics of BUOKITA' rows daily over 10 days Ploamacohinetics of BUOKITA' rows daily over 10 days and Efficacy of Reformulated Relatories of Automative and Efficacy of Reformulated Relatories of Buokitane the Safety and Efficacy of Reformulated Relatories daily and Subjects   1308/2014   Yes   2108/2014   2   Yes     XW14098   144_001483   APhase IN Multicenter, Double Billing' and whiching individual subjects   1301/2014   Yes   25/11/2014   21   Yes     XW14107   144_001483   Ploamacohineta with continuing General Weivos System (String With Yes)   1301/2014   1301/2014   No   Pending   Not applicable   Pending   Pending   Pending   Pending   Pending   Pending   Pending   Pending   Yes   Yes   Yes	&W14/063	14/LO/0667	Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are Co-Infected with HIV	12/06/2014	09/06/2014	Yes	13/06/2014	4	Yes		
AW14087     14L_01/1227     ELVITEGRA/NR/COB/CISTAT once daily over 10 days     1908/2014     1908/2014     Yes     2108/2014     2     Yes       AW14087     14L_01/1227     ELVITEGRA/NR/COB/CISTAT income daily over 10 days     1908/2014     1908/2014     Yes     2108/2014     2     Yes       AW14098     APhase III Multicenter, Double-Billing, Randomized, Active comparator-Comrolled Cilcular Triat to Explain the Mathy relates the Statey and Efficacy of Reformulated Ralegravir 1200 mg Onso Daily variaus Rategravir 400 mg Twice Daily, Each in Combination Subject     04/11/2014     Yes     25/11/2014     21     Yes       AW14/107     14L_01/493     Treatment-Naive HIV-1 Infected Subject     19/12/2014     19/12/2014     No     Pending     Not applicable     Pending     Deadline is 27 February 2015       AW14/107     14L_01/493     Raving Efficience web-stating Regiment web-stating Regimentweb-stating Regimentweb-stating Regiment web-stati	&W14/066	14/LO/0803	Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS- 955176 with Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects	14/07/2014	11/07/2014	Yes	29/07/2014	18	Yes		
APhase III Multicenter, Double-Blind, Randonized, Akieve and Efficacy of Reformulated Ralegravir 1200 mg Onso Daily and Efficacy of Reformulated Ralegravir 1200 mg Onso Daily and Efficacy of Reformulated Ralegravir 1200 mg Onso Daily and Efficacy of Reformulated Ralegravir 1200 mg Onso Daily objects daily to mg Twice Daily, Each in Combination Nim TRU VADA**, in Treatment-Naive HIV-1 Metaded Daily of Samphane Complexing Daily and Daily of Samphane Aphat Samphane Complexing Daily and Daily of Samphane Aphat Samphane Complexing Daily and Daily of Samphane (CNS) toxicity to Dolutogravir (CNS) toxici	&W14/087	14/LO/1227	ELVITEGRAVIR/COBICISTAT once daily over 10 days	19/08/2014	19/08/2014	Yes	21/08/2014	2	Yes		
BW14/107 14L_O/1493 pilot study to assess the feasibility of avticibing individualis (CNS) toxicity to Dottuggravir (CNS) toxicity to Dottuggra	&W14/098	14/LO/1381	A Phase III Multicenter, Double-Bind, Randomized, Adive Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Rategravir 1200 mg Onco Bally Versus Rategravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects	05/11/2014	04/11/2014	Yes	25/11/2014	21	Yes		
XW14/092 14/LO/1513 DF Tendovir DF or other Tendovir DF content = Tendovir D	&W14/107	14/LO/1493	pilot study to assess the feasibility of switching individuals receiving Efavirenz with continuing Central Nervous System	19/12/2014	19/12/2014	No	Pending	Not applicable	Pending	Deadline is 27 February 2015.	
A Dance 2. Pandonized Davide Dird. Switch Structure	&W14/092	14/LO/1513	Renal Effect of Elvitegravii/ Cobicista/ Entricitabine/ Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/ Tenofovir DF or Elavienz/ Emtricitabine/ Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/ Lamivudine in Antrietroviral Teatment-naive HIV-1 Infected Adults with	27/10/2014	14/10/2014	Yes	15/12/2014	62	Yes		
A Phase 3, Randomized, Double Blind, Switch Study to 24W14/062 EVALUE F/TAF In HV Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF		14/SC/0225	A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are	12/06/2014	06/06/2014	Yes	30/06/2014	24	Yes		